S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
Log in

Trevi Therapeutics Price Target & Analyst Ratings (NASDAQ:TRVI)

$3.88
+0.09 (+2.37 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$3.53
Now: $3.88
$3.90
50-Day Range
$3.80
MA: $4.57
$5.51
52-Week Range
$3.26
Now: $3.88
$10.62
Volume5,892 shs
Average Volume35,675 shs
Market Capitalization$69.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Analyst Ratings

Trevi Therapeutics (NASDAQ:TRVI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Trevi Therapeutics in the last 12 months. Their average twelve-month price target is $16.75, suggesting that the stock has a possible upside of 331.70%. The high price target for TRVI is $20.00 and the low price target for TRVI is $14.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.75$16.75$16.75N/A
Price Target Upside: 331.70% upside67.84% upside67.84% upsideN/A

Trevi Therapeutics (NASDAQ:TRVI) Consensus Price Target History

Trevi Therapeutics (NASDAQ:TRVI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2019Svb LeerinkInitiated CoverageOutperform ➝ Outperform$14.00High
6/3/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$18.00Medium
6/3/2019BMO Capital MarketsInitiated CoverageOutperform ➝ Outperform$15.00Medium
6/3/2019Leerink SwannInitiated CoverageOutperformMedium
6/3/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$20.00Medium
(Data available from 10/18/2017 forward)
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel